#NEWS: The CHMP of @ema.europa.eu has issued a positive opinion for our medicine in #IPF and #PPF – a major milestone in the EU review process and a step forward for people living with these serious lung diseases. Learn more: go.boehringer.com/XxUd #LifeForward #PulmonaryFibrosis

#NEWS: Our targeted therapy has received approval in China as a first-line treatment for adults with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC), making it an initial therapy option. 🧪Learn more: go.boehringer.com/_xdMW #LifeForward #Oncology #LungCancer

#NEWS: New data in NSCLC, SCLC and extrapulmonary neuroendocrine carcinoma will be presented at #ASCO26, adding to our growing body of research on targeted approaches in difficult-to-treat cancers. Learn more: go.boehringer.com/UfRlZ #LifeForward #Oncology

#NEWS: Japan’s MHWL has approved our treatment for #IPF and #PPF. Both conditions cause rapid lung-function loss, with severe quality-of-life impacts and claim many lives within just a few years of diagnosis. 🧪Learn more: go.boehringer.com/xZhV

#NEWS Today, we announced a global licensing deal w/ Immunitas Therapeutics to advance a preclinical antibody for inflammatory & autoimmune diseases. It selectively targets pathogenic immune cells at inflammation sites, w/ potential for more durable control. 🧪Learn more: go.boehringer.com/1zNK7

#NEWS: Together with Eko Health Inc., we’re launching an AI based solution to detect, visualize and grade heart murmurs in dogs. Eko Vet+™ | CANINEBEAT® AI supports veterinarians in identifying murmurs that may otherwise go unnoticed. Learn more: go.boehringer.com/6EMA5 #VetTech #LifeForward

#NEWS: Our Phase III trial in people living with #obesity or overweight without type 2 diabetes has met its co-primary endpoints. Obesity is linked to liver disease, type 2 diabetes and cardiovascular disease. Read more 👉 go.boehringer.com/Nsw9 #LifeForward

#NEWS: We’re launching a new vaccine to help prevent mastitis, one of the most common diseases in dairy cows. Designed for a two-dose administration, it offers early and long‑lasting protection. Learn more here: go.boehringer.com/m8oFO #LifeForward

Rabies is fatal once symptoms appear – but it’s preventable. Supported by our Stop Rabies program, Ecuador is accelerating efforts to eliminate dog‑mediated rabies by 2030 through vaccination, education and stronger surveillance. Read more 🧪👉 go.boehringer.com/HlQ7Y #OneHealthSummit #LifeForward

#PRESS: In 2025, we accomplished significant milestones together; we… 👉 reached more patients with our therapies than ever before 👉 invested a record EUR 6.4 bn in R&D 👉 made strong progress across Human Pharma & Animal Health with new launches and vaccines 🧪➡️ go.boehringer.com/1HN8D

#NEWS: Our global survey reveals that pet owners lack awareness of parasite risks. 43% of pet owners report parasite infections and 75% want clearer prevention advice. Read more 👉 go.boehringer.com/4yoE #vetmed #PublicHealth 🧪

#NEWS: Today, the @fda.gov approved our orally administered therapy for patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC) as an initial treatment. This marks the first approved targeted therapy for this use. Learn more: go.boehringer.com/VHCH- #LifeForward

#NEWS: New Phase II trial results in primary focal segmental glomerulosclerosis (FSGS) published in The Lancet. Primary FSGS is a rare, progressive kidney disease, which can end in kidney failure. Read more 👉 go.boehringer.com/VecpO #LifeForward

#NEWS: Advancing a promising bispecific antibody for inflammatory bowel disease This innovative approach with Simcere targets two pathways in one molecule - aiming to improve outcomes for patients living with this lifelong, progressive condition. 🧪 Learn more: go.boehringer.com/VUcXm

#NEWS: The @fda.gov has approved our new treatment for progressive pulmonary fibrosis (PPF) in adults. The approval provides hope to people living with this life-threatening condition. Learn more here: go.boehringer.com/SYRTX #LifeForward #PulmonaryFibrosis

Understanding and treating HER2driven lung cancer is a critical need. In collaboration with the @lcrf.org, we’re proud to congratulate three early career investigators, each receiving a two-year, $250K grant, to advance HER2mutated lung cancer research. Learn more here: LCRF.org/251209bi

Dr. Adrian Krainer received the Heinrich Wieland Prize for his pioneering contributions to #RNA research, leading to the first therapy for spinal muscular atrophy (SMA). He recently visited our R&D site to share some insights. Discover our research culture: go.boehringer.com/z1-T #medsky #pharmsky

#NEWS: China’s National Medical Products Administration (NMPA) has approved our new treatment for progressive #PulmonaryFibrosis (PPF). 🧪 In a field where milestones are scarce, today signals meaningful momentum for the PPF community. Learn more: go.boehringer.com/ao0kp #LifeForward

#NEWS: Our investigational targeted therapy has been awarded a Commissioner’s National Priority Voucher from the U.S. FDA. Find out more here go.boehringer.com/Fyr8N #LifeForward #Oncology

#NEWS: 🧪 Building on our partnership in geographic atrophy, we’re launching a new collaboration with @cdr-life.bsky.social. Our aim is to advance antibody-based therapies for autoimmune diseases, such as lupus, multiple sclerosis and arthritis. Read more: go.boehringer.com/FOSjl

#NEWS: We’ve acquired a pre-clinical program from Kyowa Kirin to develop small molecules targeting autoimmune diseases. Our aim is to address the root cause of these conditions and deliver long-lasting therapies. 🧪 Learn more: go.boehringer.com/MPRF #Innovation #AutoimmuneDiseases #PharmSky

#NEWS: The National Medical Products Administration (NMPA) in China has approved our new treatment for idiopathic pulmonary fibrosis (#IPF). 🧪 Learn more here: go.boehringer.com/HdX1

The immune system has the remarkable ability to identify and eliminate cancer cells. Our oncology research includes the investigation of T-cell engagers, focusing on leveraging immune mechanisms in cancer therapy. Learn more 🧪: go.boehringer.com/Ki82v #LifeForward #Oncology

#NEWS: Our latest oncology research in HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC) has been presented at #ESMO25. These advancements have the potential to fulfill patients’ unmet needs. 🧪 Find out more: go.boehringer.com/FU9K9 #LifeForward #Oncology

Living with cancer, the small, positive moments often have the biggest impact. We're here to celebrate these 'Big Little Things': small victories, time with loved ones, and everyday joys. 🧪 Discover how these moments make a difference: go.boehringer.com/YomJY #LifeForward #Oncology

#NEWS: Ten of our oncology abstracts will be presented at #ESMO25, sharing our ongoing research efforts in hard-to-treat cancers. 🧪 Learn more: go.boehringer.com/GCZ1 #LifeForward #Oncology

#NEWS:  The U.S. Food and Drug Administration (FDA) has approved the first new treatment for idiopathic pulmonary fibrosis (#IPF) in over a decade. 🧪 Learn more here: go.boehringer.com/rtx-w #LifeForward

#NEWS: New pooled phase III data in idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) presented at the European Respiratory Society (ERS) Congress 2025: go.boehringer.com/rdYYD 🧪  #ERS2025 #LifeForward

#NEWS: Our targeted cancer therapy for advanced non-small cell lung cancer (NSCLC) received Breakthrough Designation for first line use in the U.S. 🧪 Find out more here: go.boehringer.com/dz4O

#NEWS: New data available in HER2 (ERBB2)-mutant non-small cell lung cancer (NSCLC) in patients with stable, asymptomatic, and active brain metastases – underscoring our commitment to patients’ greatest needs.  🧪 Learn more about our presentation at #WCLC25: go.boehringer.com/WdAhL

We’re joining forces with @www.helmholtz-munich.de to drive new advances in fibrotic lung disease research. As leaders in fibrotic lung disease, we’re pioneering new therapies and striving towards our ultimate goal of finding a cure 🧪 Learn more: go.boehringer.com/HP-j5 #LungHealth #IPF

#NEWS for media: Our targeted cancer therapy has received approval in China for use in previously treated people with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC). 🧪 Learn more here: go.boehringer.com/YrIQ #LifeForward #Oncology

#NEWS: We are further strengthening our commitment to vision preservation by teaming up with Palatin Technologies. This partnership aims to develop a new first-in-class treatment for diabetic retinopathies. 🧪 Learn more: go.boehringer.com/py5Iu #EyeHealth #DiabeticRetinopathy #Innovation

At 37, Samantha was diagnosed with non-small cell #lungcancer (NSCLC). With support from her husband Justin and care team, she learned about #biomarker testing 🧪 to understand her cancer’s unique profile. #LifeForward #Oncology #Medsky

#NEWS for media: Our targeted cancer therapy has been approved in the U.S. for people with HER2 (ERBB2)-mutant advanced non-small cell lung cancer by the U.S. @fda.gov‬. Learn more here 👉: www.boehringer-ingelheim.com/human-health... #LifeForward #Oncology

#NEWS: With Click Therapeutics, we’re excited to announce our Phase III clinical study in people with experiential negative symptoms of schizophrenia met its primary endpoint. This is an important step forward in advancing mental health care 🧪. Learn more: go.boehringer.com/cvjNF

#NEWS: First Half of 2025 👉 EUR 14.0 billion in group net sales 👉 Zongertinib in #oncology and nerandomilast in #pulmonaryfibrosis near launch 👉 #AnimalHealth business grew by 7.6% 👉 Fast-growing pipeline in cardio-renal-metabolic diseases Learn more ➡️ go.boehringer.com/w7ce3

#NEWS: We’re kicking off a new chapter in digital health through our collaboration with Eko Health to improve heart murmur detection in dogs. We will bring an AI-powered tool to veterinarians to give dogs and pet owners more years of life to love. 🐕 #LifeForward Learn more: go.boehringer.com/4olwa

#NEWS: Tackling cardiovascular, renal and metabolic conditions together may be the key to hitting the UN’s 2030 goal of cutting early deaths from #NCDs by a third. Explore how 16 countries are tackling these challenges in the global Future Health report, launched at #WHA78. 👉 bit.ly/4jeQ6WZ

#NEWS: Pivotal FIBRONEER™-IPF and FIBRONEER™-ILD phase III full data in IPF and PPF presented at #ATS2025 and published in @nejm.org. IPF and PPF are serious conditions that can cause irreversible lung damage and continued decline in lung function. 🧪 👉 go.boehringer.com/1fG0l #LifeForward

#NEWS: We are joining forces with @tempusai.bsky.social By combining our experimental data with Tempus AI's real-world data on its AI-powered platform, we aim to pave the way for novel cancer treatments. Learn more: bit.ly/43owlqa #DataScience #Cancer #ResearchCollaboration

#NEWS: By using ViVerita's in vivo screening platform, we strive to identify higher quality targets faster, with fewer failures to accelerate the delivery of novel treatments for cancer patients with high need. 🧪

#NEWS: Together with the University of Oxford and Cumulus Neuroscience we are investigating new wearable technology. This will help gain insights into brain activity of people living with psychiatric disorders and develop new #PrecisionPsychiatry treatments. Learn more: bit.ly/4jsOIAN

#NEWS: New survey shows over 90% of animal owners trust and appreciate veterinary teams but underestimate the profession’s demands. Learn more: 👉 go.boehringer.com/o9qo Survey conducted with Kynetec. #WorldVeterinaryDay #LifeForward

Our mission is to redefine mental health care. We invest in research and forge unique partnerships to help transform lives. Though the journey is complex, we’re committed to ‘failing forward’— using every setback as a stepping stone toward progress. Learn more: bit.ly/42kZqSw #LifeForward

In our 2024 #AnnualReport Magazine titled 'Think Beyond' we reflect on our achievements and showcase some amazing stories and voices of our colleagues and other experts. Take a look at where we find our purpose, what drives us and where we strive to make a difference. ➡️ bit.ly/4cetX9m #LifeForward

#PRESS: In 2024, we 👉 invested EUR 6.2 billion in R&D 🧪 👉 helped more than 66 million patients 👉 further advanced our sustainability efforts 👉 kept working on breakthrough solutions that improve lives of humans & animals. Check it out ➡️ bit.ly/3FMzAzg

#Journalists: At our Annual #Press Conference on April 2, we'll discuss our performance and major milestones achieved in 2024 and provide an outlook for 2025 and beyond. Join us to get the latest news firsthand. Register now ➡️ bit.ly/4irOfhj

Caring for a loved one can be rewarding, but it can also take a toll on your career, relationship or health. Looking after your own wellbeing and ensuring your needs are being met are equally as important as looking after your loved ones. What are your tips for other caregivers? #SupportCaregivers

🧪#NEWS: We are looking forward to working with @saliprobiotech.bsky.social's team of scientists, to develop new medicines addressing challenging drug targets to transform patients' lives. #science #LifeForward